We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CXII
401
Churchill Capital Corp XII
CXII
$597M
| $28.8M | 0.04% |
+2,700,000
| New | +$27.8M |
|
402
Northern Trust
NTRS
$33.8B
| $28.7M | 0.04% |
164,900
+53,000
| +47% | +$8.73M |
|
403
Cabaletta Bio
CABA
$493M
| $28.5M | 0.04% |
9,174,758
+345,000
| +4% | +$1.13M |
|
|
GHXIU
404
Gores Holdings XI Inc Units
GHXIU
| $28.5M | 0.04% |
+2,808,000
| New | +$28.3M |
|
405
Benitec Biopharma
BNTC
$428M
| $28.4M | 0.04% |
2,120,672
| – | – |
|
406
Paychex
PAYX
$40.8B
| $28.3M | 0.04% |
287,346
-2,100
| -0.7% | -$199K |
|
407
Kroger
KR
$34.6B
| $28.1M | 0.04% |
505,500
+258,900
| +105% | +$16.9M |
|
408
Biogen
BIIB
$31.1B
| $28M | 0.04% |
129,599
-203,858
| -61% | -$39M |
|
409
Mettler-Toledo International
MTD
$25.9B
| $27.8M | 0.04% |
21,776
+14,852
| +215% | +$17.9M |
|
410
CG Oncology
CGON
$6.38B
| $27.7M | 0.04% |
390,458
-9,400
| -2% | -$614K |
|
411
Roper Technologies
ROP
$38.6B
| $27.7M | 0.04% |
81,901
-13,600
| -14% | -$4.64M |
|
412
DigitalBridge
DBRG
$2.98B
| $27.6M | 0.04% |
1,750,000
+650,000
| +59% | +$10.2M |
|
413
Bio-Techne
TECH
$11.3B
| $27.5M | 0.04% |
389,500
+321,900
| +476% | +$17.4M |
|
414
Lantheus
LNTH
$6.58B
| $27.4M | 0.04% |
246,755
-100,000
| -29% | -$9.32M |
|
415
Extra Space Storage
EXR
$28.7B
| $27.4M | 0.04% |
188,300
+118,200
| +169% | +$16.9M |
|
|
CRAN
416
Crane Harbor Acquisition Corp II
CRAN
| $27.4M | 0.04% |
2,700,000
| – | – |
|
417
Horizon Bancorp
HBNC
$1B
| $27.3M | 0.04% |
1,368,401
-102,741
| -7% | -$1.89M |
|
|
KBON
418
Karbon Capital Partners Corp
KBON
$446M
| $27.3M | 0.04% |
2,700,000
| – | – |
|
419
NetApp
NTAP
$36.3B
| $27.2M | 0.04% |
175,900
-800
| -0.5% | -$105K |
|
|
BFS
420
Saul Centers
BFS
$787M
| $27M | 0.04% |
723,198
-11,603
| -2% | -$405K |
|
421
Steel Dynamics
STLD
$34.5B
| $26.6M | 0.04% |
115,800
-87,200
| -43% | -$20.4M |
|
422
UDR
UDR
$11.4B
| $26.5M | 0.04% |
663,973
+145,200
| +28% | +$5.37M |
|
423
Amalgamated Financial
AMAL
$1.43B
| $26.4M | 0.04% |
575,016
-265,092
| -32% | -$11.2M |
|
|
Q
424
Qnity Electronics Inc
Q
$26.2B
| $26.4M | 0.04% |
161,600
-1,000
| -0.6% | -$147K |
|
425
Tapestry
TPR
$22.7B
| $26.4M | 0.04% |
180,100
+50,700
| +39% | +$7.26M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.